A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension - BaxAsia

Study identifier:D6970C00008

ClinicalTrials.gov identifier:NCT06344104

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Double-Blind, Randomised, Placebo-Controlled, Multicentre Study Evaluating the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension

Medical condition

Uncontrolled Hypertension

Phase

Phase 3

Healthy volunteers

No

Study drug

Baxdrostat, Placebo

Sex

All

Estimated Enrollment

300

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 08 Apr 2024
Estimated Primary Completion Date: 20 May 2026
Estimated Study Completion Date: 20 May 2026

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria